1214 related articles for article (PubMed ID: 29800211)
1. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
Dodick DW; Silberstein SD; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
JAMA; 2018 May; 319(19):1999-2008. PubMed ID: 29800211
[TBL] [Abstract][Full Text] [Related]
2. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
Ferrari MD; Diener HC; Ning X; Galic M; Cohen JM; Yang R; Mueller M; Ahn AH; Schwartz YC; Grozinski-Wolff M; Janka L; Ashina M
Lancet; 2019 Sep; 394(10203):1030-1040. PubMed ID: 31427046
[TBL] [Abstract][Full Text] [Related]
3. Fremanezumab for the Preventive Treatment of Chronic Migraine.
Silberstein SD; Dodick DW; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
N Engl J Med; 2017 Nov; 377(22):2113-2122. PubMed ID: 29171818
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Sakai F; Suzuki N; Kim BK; Tatsuoka Y; Imai N; Ning X; Ishida M; Nagano K; Iba K; Kondo H; Koga N
Headache; 2021 Jul; 61(7):1102-1111. PubMed ID: 34323290
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Sakai F; Suzuki N; Kim BK; Igarashi H; Hirata K; Takeshima T; Ning X; Shima T; Ishida M; Iba K; Kondo H; Koga N
Headache; 2021 Jul; 61(7):1092-1101. PubMed ID: 34324700
[TBL] [Abstract][Full Text] [Related]
6. Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine.
Brandes JL; Kudrow D; Yeung PP; Sakai F; Aycardi E; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y
Cephalalgia; 2020 Apr; 40(5):470-477. PubMed ID: 31752521
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.
Ashina M; Cohen JM; Galic M; Campos VR; Barash S; Ning X; Kessler Y; Janka L; Diener HC
J Headache Pain; 2021 Jul; 22(1):68. PubMed ID: 34246226
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.
Nahas SJ; Naegel S; Cohen JM; Ning X; Janka L; Campos VR; Krasenbaum LJ; Holle-Lee D; Kudrow D; Lampl C
J Headache Pain; 2021 Nov; 22(1):141. PubMed ID: 34819017
[TBL] [Abstract][Full Text] [Related]
9. Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
Ashina M; Cohen JM; Gandhi SK; Du E
Headache; 2021 Jun; 61(6):916-926. PubMed ID: 34115380
[TBL] [Abstract][Full Text] [Related]
10. Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine.
Winner PK; Spierings ELH; Yeung PP; Aycardi E; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y
Headache; 2019 Nov; 59(10):1743-1752. PubMed ID: 31675102
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study.
Sakai F; Suzuki N; Ning X; Ishida M; Usuki C; Iba K; Isogai Y; Koga N
Drug Saf; 2021 Dec; 44(12):1355-1364. PubMed ID: 34687446
[TBL] [Abstract][Full Text] [Related]
12. Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials.
Silberstein SD; McAllister P; Ning X; Faulhaber N; Lang N; Yeung P; Schiemann J; Aycardi E; Cohen JM; Janka L; Yang R
Headache; 2019 Jun; 59(6):880-890. PubMed ID: 30977520
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial.
Spierings ELH; Kärppä M; Ning X; Cohen JM; Campos VR; Yang R; Reuter U
J Headache Pain; 2021 Apr; 22(1):26. PubMed ID: 33863272
[TBL] [Abstract][Full Text] [Related]
14. Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study.
MaassenVanDenBrink A; Terwindt GM; Cohen JM; Barash S; Campos VR; Galic M; Ning X; Kärppä M
J Headache Pain; 2021 Dec; 22(1):152. PubMed ID: 34922436
[TBL] [Abstract][Full Text] [Related]
15. Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines.
Cohen JM; Dodick DW; Yang R; Newman LC; Li T; Aycardi E; Bigal ME
Headache; 2017 Oct; 57(9):1375-1384. PubMed ID: 28862758
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
[TBL] [Abstract][Full Text] [Related]
17. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.
Skljarevski V; Oakes TM; Zhang Q; Ferguson MB; Martinez J; Camporeale A; Johnson KW; Shan Q; Carter J; Schacht A; Goadsby PJ; Dodick DW
JAMA Neurol; 2018 Feb; 75(2):187-193. PubMed ID: 29255900
[TBL] [Abstract][Full Text] [Related]
18. Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.
Pazdera L; Cohen JM; Ning X; Campos VR; Yang R; Pozo-Rosich P
Cephalalgia; 2021 Sep; 41(10):1075-1088. PubMed ID: 33990144
[TBL] [Abstract][Full Text] [Related]
19. Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine.
Friedman DI; Cohen JM
Emerg Top Life Sci; 2020 Sep; 4(2):179-190. PubMed ID: 32832978
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.
Dodick DW; Goadsby PJ; Spierings EL; Scherer JC; Sweeney SP; Grayzel DS
Lancet Neurol; 2014 Sep; 13(9):885-92. PubMed ID: 25127173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]